XPhyto Therapeutics Corp. News
XPhyto Therapeutics Announces Private Placement
January 5, 2021 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY) (OTC:XPHYF) (FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce a non-brokered […]
XPhyto Completes Successful SARS-CoV-2 RT-PCR Diagnostic Test Kit Validation
December 17, 2020 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“), a next-generation bioscience accelerator, and […]
XPhyto Therapeutics Closes Investment
December 8, 2020 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY) (OTC:XPHYF) (FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that it has […]
XPhyto Therapeutics Announces Investment
December 3, 2020 (Source) — NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED […]
XPhyto Secures Exclusive Psychedelic Drug Development Agreement
November 10, 2020 (Source) — Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for […]
RE-TRANSMISSION: XPhyto Appoints European Healthcare Executive to Board of Directors
November 5, 2020 (Source) — Experienced pharma executive and consultant Per S. Thoresen joins board Advisory engagement with CorpCann AS […]
